Joshua Boger

Quick Facts

Full Name	Joshua Boger
Occupation	Biochemist
Date Of Birth	Apr 12, 1951(1951-04-12)
Age	73
Birthplace	Concord
Country	United States
Horoscope	Aries

Joshua Boger Biography

Joshua Boger is one of the most popular and richest Biochemist who was born on April 12, 1951 in Concord, United States. Joshua S. Boger was born on the 12th of April 1951, in Concord, North Carolina to Charles E. Boger, Jr. who was an industrial chemist in the field of textiles as well as Mary Snead Boger, an actor and writer.

Based on the advice from Max Tishler, Boger was appointed to work for Merck Sharp & Dohme Research Laboratories in the year 1978. He began his work on the development of hypertension medications, including an extremely potent renin antagonist. One of the most important steps in this development was the use computer-based modeling to the chemical aspects of the drug’s design.

In 1989, Boger founded Vertex Pharmaceuticals Incorporated. He has served variously as its President, CEO and Chairman of the board.

Vertex also developed Telaprevir, a protease inhibitor for treatment of hepatitis C. Telaprevir works by disabling a protein that the virus requires for replication. Scientists at Vertex first published the crystal structure for the protease of the hepatitis C virus in 1996. As part of the development process for the drug, the company developed an elaborate systems biology model in which they modeled hepatitis C’s dynamics to the level of individual patient response. Telaprevir was approved by the Food and Drug Administration as Incivek in May 2011.

Boger later attended Harvard University, where he worked alongside Jeremy R. Knowles on the Chemistry of the compound cyclodextrin. He earned his master’s degree in 1975 , and his doctorate degrees in Chemistry in 1979. He conducted postdoctoral research on molecular recognition in collaboration with Jean- Marie Lehn from the Universite Louis Pasteur in Strasbourg, France.

Joshua Boger Net Worth

Joshua Boger is one of the richest Biochemist from United States. According to our analysis, Wikipedia, Forbes & Business Insider, Joshua Boger 's net worth $5 Million. (Last Update: December 11, 2023)

Joshua S. Boger (born on April 12, 1951) is an organic chemist as well as co- founder of Vertex Pharmaceuticals Incorporated. He is regarded as an innovator on the subject of rational structure-based drug design. The drugs he developed include amprenavir is which is an HIV protease inhibitor. Telaprevir which is a protease inhibitor to treat hepatitis C as well as Kalydeco for treatment of cystic fibrosis. The year 2003 was the time Vertex has been named one of the world’s forty technology pioneers in the World Economic Forum. In the year 2012 Boger has been named the executive director for Alkeus Pharmaceuticals.

Between 1970 and in 1973 Boger was a student at Wesleyan University. In this period, Max Tishler, formerly the director of Merck Sharp and Dohme Research Laboratories was Boger’s mentor. Boger earned his bachelor’s degree in the sciences of chemistry and philosophy at Wesleyan in 1973.

Within 2 years, Boger was leading a group at Merck where he developed novel rational drug design techniques and applied them to pharmaceutical discovery and development. By 1987 Boger became senior director of basic chemistry at Merck Sharp & Dohme Research Laboratories, in charge of the departments of Biophysical Chemistry and Medicinal Chemistry of Immunology and Inflammation.

Height, Weight & Body Measurements

Joshua Boger height Not available right now. Joshua weight Not Known & body measurements will update soon.

Who is Joshua Boger Dating?

According to our records, Joshua Boger is possibily single & has not been previously engaged. As of December 1, 2023, Joshua Boger’s is not dating anyone.

Relationships Record : We have no records of past relationships for Joshua Boger. You may help us to build the dating records for Joshua Boger!

While under Boger’s leadership, the company worked on several potentially valuable drug treatments. Agenerase (amprenavir), an HIV protease inhibitor, was co-developed by Vertex and GlaxoSmithKline for the treatment of HIV/AIDS and approved by the FDA in 1999. A second related drug was submitted for approval in 2002. Lexiva (fosamprenavir) was approved by U.S. regulators on October 20, 2003.

Facts & Trivia

Joshua Ranked on the list of most popular Biochemist. Also ranked in the elit list of famous people born in United States. Joshua Boger celebrates birthday on April 12 of every year.

Boger retired as CEO of Vertex as of May 23, 2009, but remained on the Vertex Board of directors until June 2017. The history of Vertex has been chronicled by journalist Barry Werth in The Billion-Dollar Molecule (1995) and The Antidote.